Wire · opportunities
FDA Approves Belzutifan Plus Lenvatinib for Advanced Clear Cell RCC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 September 2026 · Fusion42 review
The FDA approved the combination of belzutifan and lenvatinib for adults with advanced clear cell renal cell carcinoma who progressed after PD-1/PD-L1 inhibitor therapy, based on the phase 3 LITESPARK-011 trial showing improved progression-free survival and objective response rate versus cabozantinib. Safety warnings require monitoring for embryo-fetal toxicity, anemia, hypoxia, and cardiovascular effects.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 24 Sep 2026 and 28 Sep 2026.
◆ ◆ The Wire takeaway
Your oncology biotech or medtech startup now confronts a new approved combo therapy altering ccRCC treatment after checkpoint inhibitors. Immediate moves include targeting patients refractory to PD-1/PD-L1 therapy while preparing for tighter clinical management demands around toxicities.
◆ Coverage
8 sources · first reported 24 Sep 2026 · latest 28 Sep 2026
◆ Topics